{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:01:56Z","timestamp":1777471316587,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Swiss Society for Multiple Sclerosis"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["FOG784"],"award-info":[{"award-number":["FOG784"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["SPP1267"],"award-info":[{"award-number":["SPP1267"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["HU842\/5-1"],"award-info":[{"award-number":["HU842\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030_135619"],"award-info":[{"award-number":["310030_135619"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.neuropharm.2014.05.012","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T06:02:10Z","timestamp":1400824930000},"page":"314-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice"],"prefix":"10.1016","volume":"85","author":[{"given":"Faik","family":"Imeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Fallegger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Schwalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Enzmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"Blankenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Meyer zu Heringdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-3957","authenticated-orcid":false,"given":"Thomas","family":"Homann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Kleuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Pfeilschifter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Huwiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2014.05.012_bib1","doi-asserted-by":"crossref","first-page":"39403","DOI":"10.1074\/jbc.M504140200","article-title":"Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway","volume":"280","author":"Akool","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.tem.2007.07.005","article-title":"Autocrine and paracrine roles of sphingosine-1-phosphate","volume":"18","author":"Alvarez","year":"2007","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.11.7.14903","article-title":"Targeting NF\u0138B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2","volume":"11","author":"Antoon","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clineuro.2005.01.005","article-title":"Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta","volume":"108","author":"Boz","year":"2006","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib6","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib7","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","article-title":"FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function","volume":"4","author":"Brinkmann","year":"2004","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib10","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing","volume":"160","author":"Chiba","year":"1998","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","article-title":"FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors","volume":"108","author":"Chiba","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/pr.110.003111","article-title":"International Union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib13","first-page":"213","article-title":"A\u00a0mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)","volume":"12","author":"Chun","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1189\/jlb.0904554","article-title":"Active participation of endothelial cells in inflammation","volume":"77","author":"Cook-Mills","year":"2005","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.immunol.23.021704.115628","article-title":"Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs","volume":"23","author":"Cyster","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib16","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.4049\/jimmunol.179.12.8470","article-title":"E- and P-selectin are not required for the development of experimental autoimmune encephalomyelitis in C57BL\/6 and SJL mice","volume":"179","author":"D\u00f6ring","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib17","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1172\/JCI6886","article-title":"Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions","volume":"104","author":"Dubois","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib18","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.cellsig.2007.03.011","article-title":"Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor","volume":"19","author":"Dudek","year":"2007","journal-title":"Cell. Signal."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib19","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1073\/pnas.80.12.3734","article-title":"Permanent cell line expressing human factor VIII-related antigen established by hybridization","volume":"80","author":"Edgell","year":"1983","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0531-5565(95)02010-1","article-title":"Differential effects of transforming growth factor-beta 1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts","volume":"31","author":"Edwards","year":"1996","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1432-1033.1994.tb20057.x","article-title":"Distinct signaling pathways mediate phorbol-ester-induced and cytokine-induced inhibition of erythropoietin gene expression","volume":"226","author":"Fandrey","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1750-3639.2008.00182.x","article-title":"FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage","volume":"19","author":"Foster","year":"2009","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1189\/jlb.1103567","article-title":"Sphingosine 1-phosphate and its type 1 G protein-coupled receptor: trophic support and functional regulation of T lymphocytes","volume":"76","author":"Goetzl","year":"2004","journal-title":"J.\u00a0Leukoc. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1124\/mol.108.049783","article-title":"Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions","volume":"74","author":"Gonzalez-Cabrera","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib25","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.4049\/jimmunol.169.8.4084","article-title":"Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate","volume":"169","author":"Graeler","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1096\/fj.03-0910fje","article-title":"The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors","volume":"18","author":"Gr\u00e4ler","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1172\/JCI0213595","article-title":"Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice","volume":"109","author":"Graesser","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib28","doi-asserted-by":"crossref","first-page":"e35129","DOI":"10.1371\/journal.pone.0035129","article-title":"In\u00a0vitro and in\u00a0vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody","volume":"7","author":"Harris","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib29","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1476-5381.1994.tb17160.x","article-title":"Stimulation by extracellular ATP and UTP of the mitogen-activated protein kinase cascade and proliferation of rat renal mesangial cells","volume":"113","author":"Huwiler","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbalip.2006.02.007","article-title":"Histamine increases sphingosine kinase-1 expression and activity in the human arterial endothelial cell line EA.hy 926 by a PKC-alpha-dependent mechanism","volume":"1761","author":"Huwiler","year":"2006","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.critrevonc.2007.04.010","article-title":"Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy","volume":"63","author":"Huwiler","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib32","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bcp.2007.12.018","article-title":"New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets","volume":"75","author":"Huwiler","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pharmthera.2009.06.008","article-title":"Lipids as targets for novel anti-inflammatory therapies","volume":"124","author":"Huwiler","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.chembiol.2005.04.019","article-title":"S1P1-selective in\u00a0vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate","volume":"12","author":"Jo","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib38","first-page":"429","article-title":"Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P","volume":"3","author":"Matsuyuki","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11910-011-0216-9","article-title":"Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions","volume":"11","author":"Mehling","year":"2011","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-pathol-011110-130224","article-title":"Mechanisms of leukocyte transendothelial migration","volume":"6","author":"M\u00fcller","year":"2011","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pupt.2011.01.017","article-title":"The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in\u00a0vitro and aggravated ventilator-induced lung injury in mice","volume":"24","author":"M\u00fcller","year":"2011","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib42","doi-asserted-by":"crossref","first-page":"9082","DOI":"10.1074\/jbc.M610318200","article-title":"Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor","volume":"282","author":"Oo","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib43","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1164\/rccm.200309-1258OC","article-title":"Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury","volume":"169","author":"Peng","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib44","doi-asserted-by":"crossref","first-page":"47281","DOI":"10.1074\/jbc.M306896200","article-title":"Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability","volume":"278","author":"Sanchez","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib46","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1476-5381.2011.01260.x","article-title":"Pharmacological relevance and potential of sphingosine 1-phosphate in the vascular system","volume":"163","author":"Schuchardt","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib60","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1476-5381.2010.00818.x","article-title":"Sphingosine kinase 1 is critically involved in nitric oxide-mediated human endothelial cell migration and tube Formation","volume":"160","author":"Schwalm","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1124\/jpet.108.148163","article-title":"Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to Prolonged efficacy j","volume":"328","author":"Senksen","year":"2009","journal-title":"Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib48","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.4049\/jimmunol.1100935","article-title":"In\u00a0vivo analysis of uropod function during physiological T cell trafficking","volume":"187","author":"Soriano","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib49","series-title":"Novel Sphingolipid Heterocyclic Compounds as Modulators of Sphingolipid Signalling and Uses Thereof","author":"Stark","year":"2012"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4049\/jimmunol.156.3.1221","article-title":"Vascular endothelial platelet endothelial adhesion molecule-1 (PECAM-1) expression is decreased by TNF-alpha and IFN-gamma. Evidence for cytokine-induced destabilization of messenger ribonucleic acid transcripts in bovine endothelial cells","volume":"156","author":"Stewart","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib51","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10571-004-1380-0","article-title":"Pharmacological targeting of ICAM-1 signaling in brain endothelial cells: potential for treating neuroinflammation","volume":"25","author":"Turowski","year":"2005","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1183\/09031936.00047810","article-title":"FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl","volume":"38","author":"Wang","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib53","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1161\/ATVBAHA.107.151456","article-title":"PECAM-1: a multi-functional molecule in inflammation and vascular biology","volume":"27","author":"Woodfin","year":"2007","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib54","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.bjp.0706452","article-title":"The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells","volume":"147","author":"Xin","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jns.2006.11.021","article-title":"Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators","volume":"259","author":"Yong","year":"2007","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib56","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1182\/blood-2005-07-2628","article-title":"Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720","volume":"107","author":"Zemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2014.05.012_bib57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1165\/rcmb.2010-0422OC","article-title":"Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression","volume":"45","author":"Zhao","year":"2011","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2014.05.012_bib59","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1016\/j.tetlet.2010.05.051","article-title":"Efficient chromatography-free synthesis of the oxy-analogue of fingolimod","volume":"51","author":"Zivkovic","year":"2010","journal-title":"Tetrahedron Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390814001798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T10:38:37Z","timestamp":1689244717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390814001798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":58,"alternative-id":["S0028390814001798"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2014.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}